1. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
C.A. Wijbrandts, MD, PhD, P.P. Tak, MD, PhD 
Mayo Clinic Proceedings 
Volume 92, Issue 7, Pages (July 2017)
DOI: /j.mayocp
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Potential predictors of response. ACPA = anti-citrullinated protein antibody; BMI = body mass index; RF = rheumatoid factor.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
MRP8/14 serum levels predict response to biological treatments in patients with rheumatoid arthritis. The figures show MRP8/14 serum levels in responders versus non-responders to adalimumab (A), infliximab (B) and rituximab (C), respectively. From Ann Rheum Dis. 2015;74(3): , with permission.39 MRP8/14 = myeloid-related proteins 8 and 14.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Figure 3
Preliminary treatment algorithm, adapted from Rheumatology (Oxford). 2012;51(4): , with permission.25 ∗Abatacept and tocilizumab can also be selected as first biologic disease-modifying antirheumatic drug. Rituximab initial non-responders switch to different mechanism of action. ∗∗ JAK inhibitor recommended for use after failure of biologic disease-modifying antirheumatic drugs.103 ACPA = anti-citrullinated protein antibody; csDMARD = conventional synthetic disease-modifying antirheumatic drug; JAK = janus kinase; RA = rheumatoid arthritis; RF = rheumatoid factor; TNF = tumor necrosis factor.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions